Paysign Q2 revenue up 33%, beats analyst estimates

Paysign

05/08/2025 22:00

Overview

Paysign Q2 2025 revenue grows 33.1%, beating analyst expectations

Adjusted EBITDA for Q2 2025 beats consensus, rising 101.8% yr/yr

Company added 123 net plasma centers, exiting quarter with 607 centers

Outlook

Paysign revises full-year 2025 revenue to $76.5 mln-$78.5 mln

Company expects Q3 2025 revenue between $19.5 mln and $20.5 mln

Paysign sees plasma revenue flat, pharma revenue up 145% in 2025

Company expects Q3 2025 gross profit margin around 59%

Result Drivers

PHARMA GROWTH - Pharma patient affordability revenue surged 189.9% due to new programs and increased claims processing

PLASMA CHALLENGES - Plasma revenue declined 4.7% amid industry oversupply, despite adding 123 net plasma centers

COST INCREASES - Costs rose due to growth in pharma programs, wage inflation, and onboarding of new plasma centers

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$19.08 mln
$18.70 mln (5 Analysts)
Q2 EPS
$0.02
Q2 Net Income
$1.39 mln
Q2 Adjusted EBITDA
Beat
$4.51 mln
$4.39 mln (5 Analysts)
Q2 Gross Margin
61.6%


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the business support services peer group is "buy"

Wall Street's median 12-month price target for Paysign Inc is $8.00, about 10.5% above its August 4 closing price of $7.16

Press Release: ID:nBw3lXwhGa

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)